JNJ Days sales outstanding
Days sales outstanding at Johnson & Johnson rose to 66.6 days in fiscal 2025, from 61.0 days in 2024.
Year-end receivables divided by total revenue, times 365. Both inputs as filed.
SOURCE: us-gaap:AccountsReceivableNetCurrent + us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · EDGAR CompanyFacts · CIK 200406 · EDGAR ↗ · FY2022–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Receivables | Revenue | DSO |
|---|---|---|---|
| FY2025 | $17.2B | $94.2B | 66.6 days |
| FY2024 | $14.8B | $88.8B | 61.0 days |
| FY2023 | $14.9B | $85.2B | 63.7 days |
| FY2022 | $15.3B | $78.7B | 70.8 days |
Cross-checks touching this measure FROM THE FILING REVIEW
◐ PARTLYproduct revenue concentration
The quoted figures do not map one-for-one onto a filed line on this page; carried as partly supported.
FY2025 10-K · FULL RECONCILIATION →✓ MATCHESproduct revenue concentration
Every quoted figure reconciles to the filed lines: 6.5% against total revenues.
FY2025 10-K · FULL RECONCILIATION →◐ PARTLYsales growth
2 of 3 quoted figures reconcile ($94.2 billion against total revenues; 6.0% against total revenues); 4.3% does not map to a filed line on this page — carried as partly supported.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHInventory vs revenue pace
Inventory grew +8.0pp faster than revenue. Carried as watch (7pp threshold).
FY2025 10-K · FULL RECONCILIATION →✓ CLEANReceivables pace
Days sales outstanding moved +5.6 days — inside the ±7-day watch threshold.
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Days sales outstanding across coverage → · JNJ company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.